Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-11-21
1999-10-12
Burns, Brian M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514508, 560 43, 560 35, A01N 3712, A01N 3752, C07C22928
Patent
active
059656140
ABSTRACT:
Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
REFERENCES:
patent: 3598859 (1971-08-01), Yates et al.
patent: 3761508 (1973-09-01), Haddock et al.
patent: 3882162 (1975-05-01), Clayton
patent: 3994713 (1976-11-01), Haddock et al.
patent: 4260782 (1981-04-01), Grieder et al.
patent: 4267355 (1981-05-01), Scott et al.
patent: 4492683 (1985-01-01), Nagpal
patent: 4619685 (1986-10-01), Kamuro et al.
patent: 5478857 (1995-12-01), Clemens et al.
Patent Abstracts of Japan, vol. 006, No. 208 (C-130), Oct. 20 1982--& JP 57 116003 A (Mitsui Toatsu Kagaku KK), Jul. 19 1982.
DeVries, Vern G., et al., "Potential antiatherosclerotic agents.4.'(Functionalized-alkyl) amino acid analogs of cetaben", J. Med. Chem., 26 (10):1411-21 (1983).
Pirkle, William H., et al., "Preparation of N-(2-naphthyl)-2-amino acids and esters of high enantiomeric purity", J. Or. Chem., 51 (1):102-5 (1986).
Ramamurthy, B., et al., "Synthesis and antitubercular activity of N-(2-napthyl) glycine hydrazide analogs", J. Med. Chem., 32 (11):2421-6 (1989).
Pirkle, William H., et al., "Chromatographic separation of the enantiomers of 2-carboalkoxyindolines and N-aryl-alpha.-amino esters on chiral stationary phases derived from N-(3-5-dinitrobenzoyl)-.alpha.-amino acids", J. Chromatogr., 348 (1): 89-96 (1996).
Pirkle, William H., et al., "An Investigation into the role of solvation in a well characterized chiral recognition system", J. Liq. Chromatogr., 14(11):2027-42 (1991).
Hyun, Myung Ho, et al., "A new chiral stationary phase being both.pi.-acidic and.pi.-basic sites dervied from (S)-tyrosine chromatographic resolution of racemates", Chem. Lett., (8):1463-6 (1994).
Kamuro, et al., Chem. Abstracts 106:22836h (1987).
Chemical Abstracts, vol. 54, No. 11, Jun. 10 1960.
Ogawa, et al., A New Method for Preparing D-Penicillamine. Reaction of Benzylpenicilloic Acid .beta.-Amides with Arylamines, Chem. Pharm. Bull., 36(6):1957-1962 (1988).
Smith, et al., .alpha.-App Processing as a Therapuetic Target for Alzheimer's Disease, Pharmaceutical Design, Current 3 439-445 (1997).
Cordell, .beta.-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease, Annu. Rev. Pharmacol. Toxicol. 34:69-89 (1994).
Audia James E.
Folmer Beverly K.
John Varghese
Latimer Lee H.
Nissen Jeffrey S.
Athena Neurosciences, Inc.
Burns Brian M.
Davis Brian J.
LandOfFree
N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-653153